Oral Presentation ESA-SRB-AOTA 2019

Rapid detection of papillary thyroid carcinoma by fluorescence imaging using a γ-glutamyltranspeptidase-specific probe: A pilot study (#146)

Rumi Hino 1 , Naoko Inoshita 2 , Toyoki Yoshimoto 2 , Makiko Ogawa 2 , Daisyu Miura 3 , Ryoko Watanabe 4 , Kenta Watanabe 4 , Mako Kamiya 5 , Yasuteru Urano 5
  1. Sports and Health Science, Daito Bunka University, Higashimathuyama-shi, Saitama, Japan
  2. Department of Pathology, Toranomon Hospital, Minato-ku, Tokyo, Japan
  3. Akasaka Miura Clinic, Akasaka, Minato-ku, Japan
  4. Department of Otolaryngology, Toranomon Hospital, Toranomon, Minato-ku, Japan
  5. Graduate School of Pharmaceutical Sciences, The University of Tokyo, Bunkyo-ku, Tokyo, Japan

Background: Nodular lesions of the thyroid gland, including papillary thyroid carcinoma (PTC), adenomatous nodule and follicular adenoma, may be difficult to diagnose by imaging, such as in ultrasonic echo testing, or by needle biopsy. Definitive diagnosis is made by pathological examination but takes several days. A more rapid and simple method to clarify whether thyroid nodular lesions are benign or malignant is needed. Fluorescence imaging with γ-glutamyl hydroxymethyl rhodamine green (gGlu-HMRG) uses γ-glutamyltranspeptidase (GGT), a cell-surface enzyme, to hydrolyze the γ-glutamyl peptide and transfer the γ-glutamyl group. GGT is overexpressed in several cancers, such as breast, lung, and liver cancers. This imaging method is rapid and useful for detecting such cancers. In this study, we tried to develop a rapid fluorescence detection method for clinical samples of thyroid cancer, especially papillary carcinoma.

Methods: Fluorescence imaging with gGlu-HMRG was performed to detect PTC using 23 surgically resected clinical samples. A portable imaging device conveniently captured white-light images and fluorescence images with blue excitation light. Hematoxylin-eosin (HE) staining was used to evaluate which fluorescent regions coincided with cancer, and immunohistochemical examination was used to detect GGT expression.

Results: All 16 PTC samples exhibited fluorescence after topical application of gGlu-HMRG, whereas the normal sections of each sample showed no fluorescence. HE staining revealed that each fluorescent region corresponded to a region with carcinoma. The PTC samples also exhibited GGT expression, as confirmed by immunohistochemistry.

Conclusions: All PTC samples were detected by fluorescence imaging with gGlu-HMRG. Thus, fluorescence imaging with gGlu-HMRG is a rapid, simple, and very useful detection tool for PTC.